Prasugrel HydrochlorideThird Party Manufacturing in India

Prasugrel Hydrochloride is a third-generation thienopyridine P2Y12 platelet receptor inhibitor that acts as a prodrug requiring in vivo metabolic activation. Following oral administration, prasugrel undergoes rapid hydrolysis by carboxylesterases in the intestine to a thiolactone intermediate, which is then converted to its active metabolite by cytochrome P450 enzymes, primarily CYP3A4 and CYP2B6, with contributions from CYP2C9 and CYP2C19. This two-step activation process is more efficient than the multi-step activation of clopidogrel, resulting in faster onset, higher plasma concentrations, and more consistent inhibition of platelet aggregation across the patient population. The active metabolite contains a free thiol group that forms an irreversible disulfide bond with cysteine residues on the P2Y12 purinergic receptor on the platelet surface, specifically targeting the Cys17 and Cys270 residues. This covalent modification permanently blocks adenosine diphosphate binding to the P2Y12 receptor, preventing the receptor-mediated activation of the glycoprotein IIb/IIIa complex, which is the final common pathway for platelet aggregation and fibrinogen-mediated platelet cross-linking. By irreversibly inhibiting the P2Y12 receptor for the lifespan of the platelet (approximately seven to ten days), prasugrel provides profound and sustained inhibition of adenosine diphosphate-induced platelet aggregation, significantly reducing the risk of thrombotic events in patients with acute coronary syndromes undergoing percutaneous coronary intervention.

Therapeutic Uses

Prasugrel Hydrochloride is prescribed for the prevention of atherothrombotic events in patients with acute coronary syndrome:

• Acute Coronary Syndrome Undergoing PCI: Prasugrel is indicated for the reduction of thrombotic cardiovascular events including stent thrombosis, myocardial infarction, and cardiovascular death in patients with acute coronary syndrome who are managed with percutaneous coronary intervention.
• ST-Elevation Myocardial Infarction: Provides more rapid and consistent platelet inhibition than clopidogrel in STEMI patients, reducing the risk of early stent thrombosis.
• Non-ST-Elevation Myocardial Infarction: Indicated for medically managed NSTEMI patients who undergo delayed PCI, with superior efficacy compared to clopidogrel.
• High-Risk Diabetic Patients: Demonstrates particular efficacy in diabetic patients with acute coronary syndrome, a subgroup that typically has higher platelet reactivity and thrombotic risk.

Prasugrel is typically co-administered with low-dose aspirin (dual antiplatelet therapy) for the recommended duration following PCI. The lower strength of 2mg is used for maintenance therapy in appropriate patient populations, while the loading dose is typically 10mg.

Why Manufacturers Choose Prasugrel Hydrochloride

Prasugrel is a potent third-generation P2Y12 inhibitor that offers superior efficacy over clopidogrel for ACS patients undergoing PCI, with faster onset and more consistent platelet inhibition independent of CYP2C19 genetic polymorphisms. The molecule is recommended in international cardiology guidelines and is included in the WHO Essential Medicines List for acute coronary syndrome management. The 2mg and 4mg tablet strengths allow manufacturers to serve the growing Indian cardiology market, where the burden of premature coronary artery disease is among the highest globally. Indian WHO-GMP manufacturers with expertise in moisture-sensitive formulations can produce prasugrel tablets for domestic PCD networks and cost-competitive export to regulated markets. The availability of authorized generics and the expiry of key patents create significant market access opportunities for Indian manufacturers.